Among health care-associated MRSA strains, all AUS-2 and AUS-3 isolates were multidrug-resistant, and UK EMRSA-15 isolates were resistant to ciprofloxacin and erythromycin (50%) or to ciprofloxacin alone (44%). Almost all (98%) of CA-MRSA strains were non-multiresistant. Conclusions: Community-onset MRSA continues to spread throughout Australia. The hypervirulence determinant PVL is often found in two of the most common CA-MRSA strains. The rapid changes in prevalence emphasise the importance of MJA 2006; 184: 384-388 ongoing surveillance.
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and Europe. 3 These reports have a number of findings in common including: lack of association with risk factors for health care-associated acquisition of MRSA; lack of resistance to non-β-lactam antibiotics; frequent association with indigenous populations; and association with subcutaneous abscess formation and necrotising pneumonia. The latter clinical conditions have been shown to correlate strongly with possession of the genes for Panton-Valentine leukocidin (PVL), an extracellular toxin that destroys leucocytes and causes tissue necrosis. 3, 4 In Australia, non-multiresistant MRSA associated with community infection (CA-MRSA) was first observed in Western Australia in the early 1990s, initially in Indigenous people in remote communities, and became known as WA-MRSA. 5 Subsequently, other strains of CA-MRSA appeared in WA. Infection caused by CA-MRSA was first noted in the eastern states in the mid-1990s. 6 Studies in Queensland 7 and New South Wales 8 initially reported a strong association between community-acquired infection with non-multiresistant MRSA and Polynesian background. The "south-west Pacific" (SWP) strain of CA-MRSA causing these infections was indistinguishable from that reported previously in Auckland, New Zealand, 7, 8 and was initially characterised by the western Samoan phage typing pattern. A second strain, the "QLD" strain, was first identified in Queensland in 2000, causing community-acquired infection in people of European background. 9 Both the SWP and QLD strains, but not the WA strains, usually carry PVL genes and are associated with abscess formation, bacteraemia and necrotising pneumonia. 3, 10, 11 However, PVL genes are carried on prophages, which are capable of generating bacteriophages (viruses that infect baceria) and consequently have the potential to spread to other strains of S. aureus.
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The epidemiology of community-onset MRSA can be confusing. Because of the differences in virulence, spectrum of infection and antibiotic sensitivity patterns, it is important to distinguish between infections caused by MRSA strains circulating in the community and not found in hospitals, and infections with onset in the community caused by health care-associated strains (HA-MRSA). The spread of the latter into the community is well documented, although these strains do not spread readily from person to person in the community. 13 The distinction between these two types of acquisition is based on the patient' s risk factors for health care acquisition, such as recent hospitalisation, surgery, antibiotic medication, chronic medical conditions, long-term care and health care occupational status.
14 It is also possible to discriminate between these epidemiologically distinct strains by a variety of molecular typing methods.
The Australian Group for Antimicrobial Resistance (AGAR) previously established that the predominant MRSA strains circulating in the community are WA-1, SWP and QLD, which are now widely dispersed geographically. 15 This report describes changes in prevalence and geographic range of community-associated strains and the extent of PVL gene carriage in community-associated strains.
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METHODS
Survey method
Isolates The results were compared with two previous similar surveys which used the same isolate inclusion criteria and involved the same laboratories, except that two fewer teaching hospital laboratories participated (one in Newcastle and one in Melbourne). 15 Isolate characteristics S. aureus was identified by standard methods, as described elsewhere. 15 Susceptibility testing was performed by agar dilution according to Clinical Laboratory Standards Institute methodology, using a single breakpoint concentration of antimicrobial. 16 Antimicrobials were incorporated into agar plates at the following concentrations: penicillin G, 0.125 mg/L; oxacillin, 2 mg/L; vancomycin, 2 mg/L; teicoplanin, 2 mg/L; rifampicin, 1 mg/L; fusidic acid, 1 mg/L; gentamicin, 4 mg/L; chloramphenicol, 8 mg/ L; erythromycin, 0.5 mg/L; clindamycin, 0.5 mg/L; tetracycline, 4 mg/L; trimethoprim, 8 mg/L; ciprofloxacin, 1 g/L; and mupirocin, 1 mg/L. An antibiotic-free control plate and five control organisms were included in each batch. 15 Resistogram typing was performed by disk diffusion against a panel of six chemicals and dyes, as previously described. 15 Coagulase gene restriction fragment length polymorphism typing was performed as described elsewhere. 15 Pulsed-field gel electrophoresis (PFGE) of chromosomal DNA was performed using the CHEF DR III System (Bio-Rad Laboratories, Sydney, NSW) and interpreted as described elsewhere. 15 Representative isolates were characterised by multilocus sequence typing (MLST) and staphylococcal chromosomal cassette mec (SCCmec) typing (where mec is the mobile genetic element responsible for methicillin resistance, classifiable into five major types), with results interpreted as described previously. 15 Strains are reported with their common names (eg, WA-1) followed by the sequence type (ST), methicillin resistance phenotype, and SCCmec type (I to V) (eg, ST1-MRSA-IV). Strains are classified into two groups on the basis of previously published evidence: those implicated in health care-associated infection (HA-MRSA); and those implicated in community-associated infection (CA-MRSA). 15 CA-MRSA isolates were assayed for the presence of PVL genes using polymerase chain reaction (PCR) primers for a 1554-bp region from lukS-PV and lukF-PV as follows: forward, 5´ GGCCTTTCCAATACAATATTGG 3´; and reverse, 5´ CCCAATCAACTTCATAAATTG 3´. 17 
Statistical analysis
We determined the proportions of S. aureus isolates which were considered CA-MRSA and HA-MRSA in each surveillance period and in each city, and also the proportions of the six major HA-MRSA and CA-MRSA strain types among all HA-MRSA and CA-MRSA isolates, respectively. Differences in proportions were tested over the survey periods using the χ 2 test for trend, where data were available for all three survey periods, or a test for the difference between two proportions, where data were available for only two survey periods. Differences were tested between cities and within cities over the survey periods. All tests for significance were two-sided with α set at the 5% level and were performed using Epi Info version 6.0.4 (Centers for Disease Control and Prevention, Atlanta, Ga, USA).
The survey did not require ethical approval as all S. aureus isolates were from routine diagnostic specimens referred to the participating laboratories; information pertaining to isolates was de-identified; and there was no change to the routine processing or reporting practices in the participating laboratories. The proportion of S. aureus isolates which were HA-MRSA and CA-MRSA differed significantly between the three surveys (P = 0.006 and P = 0.001, respectively; Box 1). However, when analysed by city, HA-MRSA proportions differed significantly between surveys only in Darwin (P = 0.03). N e w c a s t l e n a n a 9 6 n a n a 8 ( 8 % ) -n a n a 5 ( 5 % ) - 
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Significant increases in CA-MRSA occurred over the same period in four cities: Darwin (5% to 20%, P = 0.003), Brisbane (5% to 13%, P < 0.0001), Sydney (5% to 8%, P = 0.04), and Adelaide (3% to 7%, P = 0.03). The total proportion of CA-MRSA also increased significantly, from 4. Community-associated strains Three major strains of CA-MRSA predominated in all three surveys, with WA-1 (ST1-MRSA-IV) consistently the most common CA-MRSA strain (Box 2A). This strain is isolated throughout the country, but represents a lower proportion of MRSA in the eastern states than in the west. The proportion of isolates that were strain WA-1 did not change significantly over the three survey periods (P = 0.89).
The QLD strain (ST93-MRSA-IV) is now the second most common CA-MRSA strain and has increased significantly since 2000 (P = 0.0004), with a 1. Health care-associated strains Among HA-MRSA strains, the proportion of AUS-2 (subtype of ST239-MRSA-III) decreased significantly over the three surveys (P = 0.0003), while there was no significant trend for AUS-3 (also a subtype of ST239-MRSA-III) (P = 0.46) (Box 2B). None of the participating cities experienced a significant change in the other major strain, UK EMRSA-15 (ST22-MRSA-IV) over the three survey periods, nor was there a significant change overall (P = 0.17). Two isolates of 
Isolate characteristics
Antibiotic resistance phenotype differed strikingly between HA-MRSA and CA-MRSA. All AUS-2 and AUS-3 (HA-MRSA) isolates were resistant to at least four non-β-lactam antimicrobials: 86% were resistant to the combination of gentamicin, erythromycin and tetracycline; and only 4% were sensitive to gentamicin. UK EMRSA-15 isolates were usually resistant to ciprofloxacin and erythromycin (50%) or ciprofloxacin alone (44%), and differed from all other MRSA isolates in being urease-negative (with the exception of one WA-1 isolate with no non-β-lactam resistance). On the other hand, 60% of CA-MRSA isolates were resistant only to β-lactams, and 29% were resistant to only one other antimicrobial, while 2% were resistant to more than three non-β-lactams, and one isolate was resistant to gentamicin. The PVL gene was detected in 90 isolates belonging to five CA-MRSA strains. The proportion of PVL-positive isolates varied markedly between strains (P < 0.0001): WA-17, 1 (100%; 95% CI, 3%-100%); QLD, 56 (97%; 95% CI, 88%-100%); SWP, 25 (96%; 95% CI, 80%-100%); WA-12, 3 (75%; 95% CI, 19%-99%); and WA-1, 5 (8%; 95% CI, 3%-17%). The proportion of PVL-positive isolates also varied markedly between cities (P < 0.0001): Canberra, 100%; Sydney, 80%; Brisbane, 74%; Darwin, 42%; Newcastle, 17%; Adelaide, 15%; Perth, 11%; and Melbourne and Hobart, 0. Thirteen (14%) of the PVL-positive isolates were resistant to erythromycin.
DISCUSSION
The concurrent emergence and expansion of multiple PVL-positive CA-MRSA clones on different continents has been rapid and striking. This epidemic has been very well documented in Australia by AGAR: annual studies conducted exclusively in teaching hospitals from 1989 to 1999 showed that non-multiresistant MRSA, a surrogate marker for CA-MRSA, began to increase in Perth in the early 1990s and in more easterly cities in the late 1990s. 10 The biennial studies reported here and previously have established the major strains causing community-onset MRSA infection in Australia. 15 Clearly, CA-MRSA now represents a major clinical and public health problem. The large distances between Australian cities have been no barrier to the rapid spread of the major epidemic strains, WA-1, SWP and QLD. The first two of these are pandemic strains which have appeared on multiple continents. 3, 18, 19 Demonstration of the presence of the relatively small SCCmec type IV element (one of a range of elements responsible for methicillin resistance) in increasing numbers of lineages of S. aureus is of great concern: this element is of a size (about 28 kilobases) to allow spread by bacteriophage transduction.
The increase in prevalence of CA-MRSA is due to two mechanisms: first, clonal expansion of successful lineages, such as the QLD strain; and second, the transmission of SCCmec to an increasing number of lineages of S. aureus. This raises the prospect of widespread acquisition of methicillin resistance in S. aureus, similar to the spread of penicillin resistance seen in the latter half of the 20th century, which led to penicillin resistance levels greater than 80%. 10, 20 Furthermore, the ability of CA-MRSA strains to acquire resistance to other antimicrobials will almost certainly pose a longer term challenge. While only 2% of CA-MRSA isolates were resistant to more than three non-β-lactam antimicrobials in the 2004 survey, no CA-MRSA isolates had that level of resistance in the previous two surveys.
The spread of virulence genes is also a potential problem. PVL genes are carried on a prophage and so can be transmitted to receptive strains by transduction. 12 We demonstrated the presence of PVL in five CA-MRSA strains, three of which (WA-1, QLD and SWP) are major epidemic strains. PVL has been described in WA-1 only recently, 21, 22 and clinical data on the association of this strain with severe infections are lacking. Nonetheless, it has recently been suggested that drugs that shut down ribosomal translation of proteins in S. aureus, such as clindamycin and linezolid, might decrease production of toxins such as PVL. Therefore, these drugs may be specifically indicated in the treatment of serious CA-MRSA infections. 23 This hypothesis remains to be tested in vivo.
As CA-MRSA strains are now common in many parts of Australia, it is important that doctors consider that any staphylococcal infection -acquired in the community or in hospital -may be caused by MRSA. It is important to collect appropriate microbiological specimens, such as swabs for localised infections and blood cultures for systemic infections, for culture and susceptibility testing. Delay in recognition that these infections are caused by MRSA can in turn delay definitive treatment, and this may lead to increased mortality or prolonged morbidity. 11, 24 Laboratories need to expedite detection of MRSA, report sensitivity to an appropriate range of non-β-lactam antibiotics, and provide advice on suitable antimicrobials.
The choice of empirical treatment should be guided by the severity of infection, the presence of risk factors for HA-MRSA infection, and the local prevalence of CA-MRSA. Where MRSA is likely, vancomycin is suggested for cases of severe or life-threatening infection, while linezolid may be considered as a second-line agent. 25 If infection is mild, it is still reasonable to prescribe flu(di)cloxacillin (or alternative β-lactams in cases of intolerance or allergy), given that most strains of S. aureus are still sensitive to β-lactams. However, should MRSA be isolated, therapy should be changed to an appropriate agent. A number of readily available oral agents can be used in mild to moderate infections. Clindamycin has been suggested, but may not always be appropriate because of the presence of inducible resistance in some CA-MRSA strains. 25 Erythromycin is the best indicator of this type of resistance in Australia, and we found that 14% of PVL-positive CA-MRSA isolates in this survey were resistant to erythromycin. The use of tetracyclines such as doxycycline is supported by a retrospective case series and case reports. 26 Trimethoprim-sulfamethoxazole was found to be equivalent to vancomycin in serious MRSA infections in injecting drug users, 27 and there is also evidence of its success in less serious community MRSA infections. 28 Therefore, clindamycin, doxycycline or trimethoprim-sulfamethoxazole may be used for mild to moderate CA-MRSA infections, depending on susceptibility results. However, tetracyclines should not be used in children aged under 8 years, and trimethoprim-sulfamethoxazole should not be used in infants under 8 weeks. Ongoing surveillance is essential to assess progress of the epidemic of MRSA in the community in Australia and changes in susceptibility of the epidemic strains.
